Merck-Schering Merger Requires Divestiture of Phase II Antiemetic Due To Emend's Strength
This article was originally published in The Pink Sheet Daily
Executive Summary
FTC says Schering must divest its NK-1 receptor antagonist relapitant. Merck must also sell its interest in a $2.6 billion animal health joint venture.